KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Other Accumulated Expenses (2016 - 2025)

Eli Lilly (LLY) has disclosed Other Accumulated Expenses for 17 consecutive years, with $8.5 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Accumulated Expenses rose 32.2% year-over-year to $8.5 billion, compared with a TTM value of $8.5 billion through Dec 2025, up 32.2%, and an annual FY2025 reading of $8.5 billion, up 32.2% over the prior year.
  • Other Accumulated Expenses was $8.5 billion for Q4 2025 at Eli Lilly, up from $5.2 billion in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $8.5 billion in Q4 2025 and bottomed at $2.0 billion in Q3 2022.
  • Average Other Accumulated Expenses over 5 years is $3.7 billion, with a median of $2.9 billion recorded in 2021.
  • The sharpest move saw Other Accumulated Expenses fell 23.67% in 2022, then surged 115.84% in 2024.
  • Year by year, Other Accumulated Expenses stood at $3.0 billion in 2021, then fell by 6.01% to $2.8 billion in 2022, then rose by 15.32% to $3.3 billion in 2023, then skyrocketed by 94.95% to $6.4 billion in 2024, then surged by 32.2% to $8.5 billion in 2025.
  • Business Quant data shows Other Accumulated Expenses for LLY at $8.5 billion in Q4 2025, $5.2 billion in Q3 2025, and $5.1 billion in Q2 2025.